Vraylar
Marketed by: Actavis Pharma, IncIndication: The FDA has approved Vraylar, an atypical antipsychotic, for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder. The recommended starting dose for the treatment of schizophrenia or bipolar mania is 1.5 mg/day.Dosage Form: Capsules: 1.5, 3, 4.5, and 6 mgFor More Information: www.allergan.comSpiriva Respimat
Marketed by: Boehringer Ingelheim Pharmaceuticals, IncIndication: The FDA has expanded the use of Spiriva Respimat (tiotropium bromide inhalation spray) to include long-term, once-daily maintenance treatment of asthma in patients 12 years and older. The recommended dosage for this indication is 2 inhalations of 1.25 mcg once daily.Dosage Form: Inhalation spray: 1.25 mcg tiotropium per actuation with the Spiriva Respimat inhaler; 2 actuations equal 1 dose (2.5 mcg)For More Information: www.spiriva.comHumiraÂ 
Marketed by: AbbVie, IncIndication: The FDA has expanded the use of Humira (adalimumab) to include treatment of moderate to severe hidradenitis suppurativa, an inflammatory skin disease. For other indications and the recommended dosing and administration, see the full prescribing information.Dosage Form: Injection (see the full prescribing information)For More Information: www.humira.comFycompa
Marketed by: Eisai, IncIndication: The FDA has expanded the use of Fycompa (perampanel hydrate) CIII, a noncompetitive AMPA glutamate receptor antagonist, to include adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 12 years or older with epilepsy. For dosage and administration, see the full prescribing information.Dosage Form: Tablets: 2, 4, 6, 8, 10, and 12 mgFor More Information: www.Fycompa.com
